Capital Access Group - TheraCryf | FY26 results – Ox-1 programme on track

15 hours ago

Research on TheraCryf PLC (TCF:LON) from Capital Access Group

TheraCryf has announced results for the year to March 2026 in line with management's expectations. Closing net cash was £1.5m, ahead of the post-period-end equity raise of £1.05m, leaving the company funded through FY27. More importantly, TheraCryf advanced the programme for its Ox-1 lead clinical asset flawlessly and is approaching more value inflection points ahead of first in-human trials. The target market for Ox-1 is currently worth US$42bn and growing rapidly. The company is completing the remaining clinic-enabling activities and continues to engage with potential commercial partners to maximise shareholder value in a hot area of interest for the pharma industry. Given that context, we believe TheraCryf's valuation is nugatory.

View Full Research

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Market Sectors

Cavendish maintains Buy on Vietnam Holding as FTSE upgrade supports outlook

VietNam Holding sees opportunity from Vietnam market reclassification

Cadence starts hot commissioning at Azteca

Poolbeg Pharma advances POLB 001 trial with eight participants dosed

Panther Metals books interim results, presses on with exploration at Obonga

Longspur Clean Energy - Luceco - New Help to Buy Scheme

Capital Access Group - TheraCryf | FY26 results – Ox-1 programme on track

Edison - Cobra Resources:Blue Rose drilling strengthens porphyry case

Longspur Clean Energy - Clean Power Hydrogen - New Strategy Follows Interims

Equity Development - Cohort plc - FY27 momentum maintained after a record year

Edison - Kooth:Improved profitability and growth drivers

Zeus says Rift Helium could be worth multiples of current share price

Mining Matters - Cavendish says Blencowe Resources shares could go 500% higher

Oriole has 1.2 million ounces of gold from surface at Mbe

This commodity cycle will be bigger than 2002-2007

Bradda Head poised to benefit from lithium rebound

Capital Access Group - TheraCryf | FY26 results – Ox-1 programme on track